** Cancer treatment firm Nuvation Bio's NUVB.N shares down 2.8% premarket on Fri to $5.65 after raising more capital than targeted

** NUVB late Thurs announced pricing public offering of $250 mln 0.75% convertible bonds due July 1, 2032

** Initial conversion price of $7.84 is 35% above stock's last sale of $5.81

** NUVB shares finished down ~10% on Thurs after co launched $200 mln offering to repay loan agreement, and for general purposes, including working capital, opex and capex

** Co also expects to use some proceeds to pay cost of capped call transactions; initial cap price set at $10.46, an 80% premium to last close

** Jefferies, Citigroup and Cantor Fitzgerald joint bookrunners for the offering, joined by RBC

** Through Thurs, stock down 35% YTD

** 10 of 11 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $12, per LSEG data